Mymetics Corp (MYMX)

[bow-tie]

Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate
Bárbara Fernandes,1,2 Rute Castro,1 Farien Bhoelan,3 Denzel Bemelman,3 Ricardo A. Gomes,1 Júlia Costa,2 Patrícia Gomes-Alves,1,2 Toon Stegmann,3 Mario Amacker,4,5 Paula M. Alves,1,2 Sylvain Fleury,4 and António Roldão1,2,*
Wouter L. J. Hinrichs, Academic Editor
Author information Article notes Copyright and License information Disclaimer
1iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal; tp.tebi@sednanrefb (B.F.); tp.tebi@ortsacr (R.C.); tp.tebi@semogar (R.A.G.); tp.tebi@sevlap (P.G.-A.); tp.tebi@seuqram (P.M.A.)
2ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal; tp.lnu.bqti@atsocj
3Mymetics BV, J.H. Oortweg 21, 2333 CH Leiden, The Netherlands; [e-mail] (F.B.); [e-mail] (D.B.); [e-mail] (T.S.)
4Mymetics SA, Route de la Corniche 4, 1066 Epalinges, Switzerland; [e-mail] (M.A.); [e-mail] (S.F.)
5Department of Biomedical Research (DBMR), Department of Pulmonary Medicine, Bern University Hospital, University of Bern, 3008 Bern, Switzerland
*Correspondence: tp.tebi@oadlora; Tel.: [phone]

In this study, we developed a scalable bioprocess using the insect cells-baculovirus expression vector system (IC-BEVS) to produce high-quality S protein, stabilized in its pre-fusion conformation, for inclusion in a virosome-based COVID-19 vaccine candidate.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031128/

Merck & Co. Licenses Protein Sciences’ Insect Cell Vaccine Production Platform
February 23, 2012

The PS platform uses engineered baculoviruses to generate recombinant proteins in the expresSF+ insect cell line. Protein Sciences claims the platform is fast, low cost, results in correctly folded and biologically active proteins, and is scalable to large volumes and high cell densities. The BEVS technology has already been applied to the development of prophylactic and therapeutic vaccines against infectious viruses, biodefense applications, cancer, and diabetes, as well as rAAV-based gene therapy products for lipid and CNS disorders, and biologics for wound/tissue repair, viral infections, and inflammatory diseases.
https://www.genengnews.com/topics/drug-discovery/merck-co-licenses-protein-sciences-insect-cell-vaccine-production-platform/